For example, inhibition of the tyrosine kinase of EGFR by TKIs has produced responding rates range between 10–20% in lung cancer patients; however, all patients acquired resistance within few months after treatment,[4, 5] and prostate cancer, a type of cancer where EGFR is commonly overexpressed, is innately resistant to EGFR TKIs [6, 7]. The gene discussed is EGFR; the disease is lung cancer.